Catal­ent in­tro­duces new AAV gene ther­a­py tech in aim to speed up man­u­fac­tur­ing process

As Catal­ent ven­tures fur­ther in­to the world of cell and gene ther­a­py man­u­fac­tur­ing, the New Jer­sey-based CD­MO has re­vealed its new ade­no-as­so­ci­at­ed vi­ral vec­tor plat­form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER